Core Viewpoint - China Dongfang (01763) reported a revenue of 2.858 billion RMB for the six months ending June 30, 2025, representing a year-on-year increase of 1.69% [1] - The company's profit attributable to equity shareholders was 172 million RMB, an increase of 11.33% year-on-year, with basic earnings per share of 0.54 RMB [1] - A mid-term dividend of 0.0807 RMB per share is proposed [1] Group Focus - The company focuses on two main industry directions: nuclear medical health and irradiation applications, aiming to provide comprehensive solutions in nuclear medicine and radiation therapy [1] - The business model is structured around a "6+N" industrial layout, which includes six core businesses: radionuclides, radiopharmaceuticals, nuclear medical equipment, overall solutions for nuclear medicine, radiation sources and applications, and irradiation applications [1] Business Operations - The company is engaged in the research, development, manufacturing, and sales of radioactive pharmaceuticals for diagnosis and treatment, as well as medical and industrial radiation source products [1] - It provides services such as irradiation sterilization, material modification, and the design, manufacturing, installation engineering, procurement, and construction (EPC) services of irradiation devices [1] - Additionally, the company offers nuclear medical equipment and construction services for nuclear medicine departments to hospitals and other medical institutions [1]

Group 1 - The company reported a revenue of 2.858 billion RMB for the six months ending June 30, 2025, representing a year-on-year increase of 1.69% [1] - The profit attributable to equity shareholders was 172 million RMB, an increase of 11.33% year-on-year [1] - The basic earnings per share were 0.54 RMB, and the company proposed an interim dividend of 0.0807 RMB per share [1] Group 2 - The company focuses on two main industry directions: nuclear medical health and irradiation applications, aiming to provide comprehensive solutions in nuclear medicine and radiation therapy [1] - The business model is structured around a "6+N" industrial layout, which includes six core business areas: radionuclides, nuclear pharmaceuticals, nuclear medical equipment, overall solutions for nuclear medicine, radiation sources and applications, and irradiation applications [1] - The company is engaged in the research, development, manufacturing, and sales of radioactive pharmaceuticals for diagnosis and treatment, as well as medical and industrial radiation source products [1]